BCVS 2017:PDE5抑制剂的另一妙用,可降低血栓!!!

2017-07-12 佚名 medicalnewstoday

新的初步研究发现,通常用于治疗勃起功能障碍的药物的支架可能会阻止动脉再次堵塞或变窄。 研究结果发表在AHA的“基础心血管科学”2017年科学大会上。该研究的主要作者是韩国首尔国立大学医院心脏病学系副教授Han-Mo Yang博士。

使用支架预防心脏病发作是很常见的,但是,有时候,支架植入可能导致凝血或动脉变窄。新的研究表明,普遍用于勃起功能障碍的药物可能会降低这些并发症的风险。

支架是由金属网制成的小管,插入阻塞的动脉中以保持其开放并允许血液更容易流动。

据美国心脏协会(AHA)介绍,使用支架“相当普遍”。当由于斑块的积聚而使动脉变窄时,它们被用于试图减少心脏病发作的机会。

对于一些患者,支架减少“再狭窄”的风险——动脉再狭窄。但对另一些人来说,他们可以产生相反的效果,因为区域周围组织生长过度治疗支架可使动脉再次变得狭窄或阻塞。这种情况往往发生在所谓的裸金属支架,这些支架是不涂药物的支架。


相比之下,为了防止血管闭合而被药物覆盖的支架被称为“药物洗脱支架”。

然而,有时,药物洗脱支架也可能导致其他并发症。例如,尽管进行了抗凝血治疗,但支架附近仍可发生血块。

但是新的初步研究发现,通常用于治疗勃起功能障碍的药物的支架可能会阻止动脉再次堵塞或变窄。

研究结果发表在AHA的“基础心血管科学”2017年科学大会上。该研究的主要作者是韩国首尔国立大学医院心脏病学系副教授Han-Mo Yang博士。

西地那非可降低血小板聚集

杨博士及其同事对啮齿动物进行了一系列测试,检测了西地那非药物对血液凝固的影响。

西地那非用于治疗勃起功能障碍,尽管该药物最初是作为抗高血压药物开发的。该药现在作为“伟哥”或“Revatio”出售 - 前者用于勃起功能障碍,而后者则用于帮助成年人进行肺动脉高压运动。

药物可以增加血液流动并使动脉松弛,从而使血液更自由地流动。

新研究显示西地那非“减少血小板聚集30%”。

血小板是当我们小切割时我们不会过度流血的原因之一。它们是我们血液中的细胞,可以通过结合在一起并形成血块来检测受损的血管并“进入救援”。

当然,对于容易堵塞动脉的人来说,医生可能会开出抗血小板药物,以降低心脏病发作或中风的风险。

在新研究中,杨和团队发现西地那非增加称为蛋白激酶G(PKG)的酶的活性。

PKG可以防止动脉壁在受伤后增厚,因此有助于避免在支架置入手术后出现并发症。

如作者解释,支架植入降低PKG活性,其导致动脉增厚和血小板的增加的结合。因此,PKG激活对于西地那非可以预防再狭窄的机制至关重要。

“我们的研究是有限的,只涉及动物。如果临床试验表明,西地那非可减少再狭窄支架置入后,马上可以用于临床,因为在现实世界中药物已经用于其他目的,”杨博士说。

“西地那非可能是涂抹药物洗脱支架或支架植入后口服的理想药物。”
原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1940299, encodeId=f46f1940299ae, content=<a href='/topic/show?id=b5b15526b6' target=_blank style='color:#2F92EE;'>#CVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5526, encryptionId=b5b15526b6, topicName=CVS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Mar 28 20:42:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984878, encodeId=7beb19848e813, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 12 02:42:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851485, encodeId=761c18514855f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 24 20:42:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221474, encodeId=c2592214e4bf, content=受教了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bef1976587, createdName=1e172a6bm25(暂无匿称), createdTime=Wed Jul 12 17:53:12 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221421, encodeId=c3fc22142171, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Jul 12 14:02:04 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
    2018-03-28 yese
  2. [GetPortalCommentsPageByObjectIdResponse(id=1940299, encodeId=f46f1940299ae, content=<a href='/topic/show?id=b5b15526b6' target=_blank style='color:#2F92EE;'>#CVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5526, encryptionId=b5b15526b6, topicName=CVS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Mar 28 20:42:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984878, encodeId=7beb19848e813, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 12 02:42:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851485, encodeId=761c18514855f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 24 20:42:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221474, encodeId=c2592214e4bf, content=受教了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bef1976587, createdName=1e172a6bm25(暂无匿称), createdTime=Wed Jul 12 17:53:12 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221421, encodeId=c3fc22142171, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Jul 12 14:02:04 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1940299, encodeId=f46f1940299ae, content=<a href='/topic/show?id=b5b15526b6' target=_blank style='color:#2F92EE;'>#CVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5526, encryptionId=b5b15526b6, topicName=CVS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Mar 28 20:42:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984878, encodeId=7beb19848e813, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 12 02:42:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851485, encodeId=761c18514855f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 24 20:42:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221474, encodeId=c2592214e4bf, content=受教了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bef1976587, createdName=1e172a6bm25(暂无匿称), createdTime=Wed Jul 12 17:53:12 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221421, encodeId=c3fc22142171, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Jul 12 14:02:04 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
    2017-10-24 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1940299, encodeId=f46f1940299ae, content=<a href='/topic/show?id=b5b15526b6' target=_blank style='color:#2F92EE;'>#CVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5526, encryptionId=b5b15526b6, topicName=CVS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Mar 28 20:42:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984878, encodeId=7beb19848e813, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 12 02:42:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851485, encodeId=761c18514855f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 24 20:42:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221474, encodeId=c2592214e4bf, content=受教了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bef1976587, createdName=1e172a6bm25(暂无匿称), createdTime=Wed Jul 12 17:53:12 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221421, encodeId=c3fc22142171, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Jul 12 14:02:04 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
    2017-07-12 1e172a6bm25(暂无匿称)

    受教了,感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1940299, encodeId=f46f1940299ae, content=<a href='/topic/show?id=b5b15526b6' target=_blank style='color:#2F92EE;'>#CVS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5526, encryptionId=b5b15526b6, topicName=CVS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Mar 28 20:42:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984878, encodeId=7beb19848e813, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Mon Feb 12 02:42:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851485, encodeId=761c18514855f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Oct 24 20:42:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221474, encodeId=c2592214e4bf, content=受教了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=252, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bef1976587, createdName=1e172a6bm25(暂无匿称), createdTime=Wed Jul 12 17:53:12 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221421, encodeId=c3fc22142171, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Jul 12 14:02:04 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
    2017-07-12 执着追梦

    学习,谢谢分享

    0

相关资讯

英国将“撕去”PDE5抑制剂的处方药标签

伟哥自1998年辉瑞公司推出以来,便成为了数百万人使用的最成功的药物之一。伟哥作为一种处方药,但是近日英国政府正计划以非处方药的形式出售伟哥,这样一来英国人民将不再需要医生的处方就可以服用这种药物。

选速效救心丸,还是硝酸甘油?(修订)

硝酸甘油和速效救心丸,都称得上是心绞痛患者的“救命药”。那么,在心绞痛急性发作时,到底是应该选用硝酸甘油还是速效救心丸?这两种药之间究竟怎样区别呢?一、两种药均可用于心绞痛急性发作心绞痛为冠状动脉血流量不能满足心脏需要,心肌急剧的、暂时的缺血、缺氧所引起。硝酸甘油片和速效救心丸均可用于冠心病心绞痛的治疗及预防(药品说明书)。硝酸甘油片硝酸甘油是救治心绞痛发作的首选药物。可用于冠心病心绞痛的治疗及预

AANA:麻醉前可不可以来一颗PDE5抑制剂?

近期美国麻醉护士学会(AANA)称,男性在术前一天不要使用治疗勃起功能障碍的药物!常见的包括伟哥和西力士。知道为什么术前不能吃,不做手术就能吃吗?因为一氧化氮!这些药物里含有能够舒张血管和松弛肌肉的一氧化氮,也是为什么血液可以充到小头里的原因。不过,这些药物在人体内的清除时间超过24小时。所以如果手术前吃了这些药,麻醉风险就会大大升高,麻醉时或使用其他药物时,可能出现血压的急剧下降。所以,男性在术

JAMA:PDE5抑制剂可能增加了恶性黑色素瘤的风险

    背景  对于口服勃起功能障碍药物的靶点,5型磷酸二酯酶(PDE5)抑制剂,是与恶性黑色素瘤的发展途径密切相关的一部分。最近报道西地那非使用者的恶性黑色素瘤的风险增加。    意义  为了检测使用PDE5抑制剂和黑素瘤风险之间的联系,包括特定PDE5抑制剂的数据,处方编号,和黑素瘤的阶段。    方法  

西媒盘点药物的意外疗效:PDE5抑制剂本该治心绞痛

参考消息网1月25日报道西媒称,在大多数情况下,治愈或预防某种疾病都与某个药物或某项技术背后的数千小时研究工作息息相关,有时与医生的临床眼光有关,而与运气有关的几率却远超出我们的想象。   西班牙《趣味》月刊9月号发表题为《意外治愈》的文章称,药房里出售的很多药物原本是为了治疗某个疾病而研制出来的,却意外发现对其他疾病有疗效。这些惊喜是发生于观察患者身上的副作用或接受某种疾病治疗

新型声波疗法有望替代PDE5抑制剂治疗“男性问题”

    目前科学家最新提出一种治疗男性勃起功能障碍的新方法,使用声波疗法替代伟哥药物,实验显示,声波疗法没有副作用。   腾讯科学讯 据英国每日邮报报道,伟哥的面世彻底改善了全球情侣的性生活质量,但是这种蓝色小药丸存在着副作用,会导致服用者鼻塞、头晕和听力突然下降。目前,科学家称最新发现一种独特方案,使用声波治疗严重勃起功能障碍患者。   研究